Custo-benefício das alternativas às transfusões de sangue
Hematologia
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (abre nova janela)
Fonte: Blood Transfus 2020;18(2):106-16.
Indexado: PubMed 31855149
DOI: 10.2450/2019.0248-19
https://www.ncbi.nlm.nih.gov/pubmed/31855149 (abre nova janela)
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (abre nova janela)
Fonte: Support Care Cancer 2013;21(2):485-93.
Indexado: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (abre nova janela)
Restrictive blood transfusion practices are associated with improved patient outcomes. (abre nova janela)
Fonte: Transfusion 2014;54(10 Pt 2):2753-9.
Indexado: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (abre nova janela)
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (abre nova janela)
Fonte: Clin Ther 2010;32(14):2478-93.
Indexado: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
https://www.ncbi.nlm.nih.gov/pubmed/21353116 (abre nova janela)
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (abre nova janela)
Fonte: J Pediatr Surg 2008;43(12):2235-8.
Indexado: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (abre nova janela)
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (abre nova janela)
Fonte: Blood Adv. 2022;6(3):785-92.
Indexado: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
https://pubmed.ncbi.nlm.nih.gov/34781363/ (abre nova janela)
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (abre nova janela)
Fonte: Transfusion 2017;57(9):2189-96.
Indexado: PubMed 28671296
DOI: 10.1111/trf.14191
https://www.ncbi.nlm.nih.gov/pubmed/28671296 (abre nova janela)
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (abre nova janela)
Fonte: Biol Blood Marrow Transplant 2012;18(5):813-7.
Indexado: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
https://www.ncbi.nlm.nih.gov/pubmed/22080050 (abre nova janela)
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (abre nova janela)
Fonte: Transfusion 2019;59(11):3386-95.
Indexado: PubMed 31664712
DOI: 10.1111/trf.15558
https://www.ncbi.nlm.nih.gov/pubmed/31664712 (abre nova janela)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (abre nova janela)
Fonte: Transfusion 2015;55(12):2807-15.
Indexado: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (abre nova janela)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (abre nova janela)
Fonte: Cancer 2013;119(1):107-14.
Indexado: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (abre nova janela)
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (abre nova janela)
Fonte: Cost Eff Resour Alloc 2013;11(1):16.
Indexado: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
https://www.ncbi.nlm.nih.gov/pubmed/23870502 (abre nova janela)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (abre nova janela)
Fonte: Support Care Cancer 2012;20(1):159-65.
Indexado: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (abre nova janela)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (abre nova janela)
Fonte: J Med Econ 2013;16(2):318-26.
Indexado: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
https://www.ncbi.nlm.nih.gov/pubmed/23216012 (abre nova janela)
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (abre nova janela)
Fonte: Hematology 2018;23(7):417-22.
Indexado: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
https://www.ncbi.nlm.nih.gov/pubmed/29157136 (abre nova janela)
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (abre nova janela)
Fonte: J Med Econ 2013;16(5):633-8.
Indexado: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
https://www.ncbi.nlm.nih.gov/pubmed/23425291 (abre nova janela)
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (abre nova janela)
Fonte: Transfusion 2010;50(2):487-92.
Indexado: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
https://www.ncbi.nlm.nih.gov/pubmed/19804569 (abre nova janela)
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (abre nova janela)
Fonte: Am J Hematol 2010;85(10):795-7.
Indexado: PubMed 20645429
DOI: 10.1002/ajh.21772
https://www.ncbi.nlm.nih.gov/pubmed/20645429 (abre nova janela)
Increased hospital costs associated with red blood cell transfusion. (abre nova janela)
Fonte: Transfusion 2015;55(5):1082-9.
Indexado: PubMed 25488623
DOI: 10.1111/trf.12958
https://www.ncbi.nlm.nih.gov/pubmed/25488623 (abre nova janela)